US EditionPublished • loading... • Updated
AstraZeneca India gets CDSCO approval for additional indication for Osimertinib in unresectable EGFR-mutated lung cancer - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AstraZeneca India gets CDSCO approval for additional indication for Osimertinib in unresectable EGFR-mutated lung cancer - Express Pharma
AstraZeneca India Pharma announced it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of Osimertinib 40mg and 80mg tablets for an additional indication. The approval marks a critical step forward with Osimertinib as monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) harbouring EGFR exon 19 deletions o…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
